TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05802615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARITY
Description: The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
Study: NCT04930094

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Description: Secukinumab
Study: NCT06553872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
Study: NCT05624034

Intervention type: DEVICE
Intervention: Electrogastrography
Description: Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis

Intervention type: DEVICE
Intervention: Electrogastrography
Description: Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis

Intervention type: DEVICE
Intervention: Electrogastrography
Description: Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
Study: NCT05312060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC Pneumatic compression
Description: Pneumatic compression of the operated limb
Study: NCT06393387

Intervention type: DRUG
Intervention: DTG/3TC versus BIC/F/TAF
Description: A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).

Intervention type: DRUG
Intervention: DTG/3TC versus BIC/F/TAF
Description: A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
Study: NCT05990907

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Remote ischemic preconditioning
Description: The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
Study: NCT04859517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG20
Description: Single dose of ADG20

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study: NCT04782739

Intervention type: OTHER
Intervention: None - Descriptive study
Description: Descriptive study

Intervention type: OTHER
Intervention: None - Descriptive study
Description: Descriptive study

Intervention type: OTHER
Intervention: None - Descriptive study
Description: Descriptive study
Study: NCT06553872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
Study: NCT05312060

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AE Antithromboembolic exercises
Description: Exercises for the edema
Study: NCT05212142

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: verbal education
Description: Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: verbal education, visual aids, and motivational interviewing
Description: Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
Study: NCT05123417

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow up
Description: Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
Study: NCT04121013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mothership
Description: Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
Study: NCT06505642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle-based confocal laser endomicroscopy
Description: needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
Study: NCT05235607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
Description: subcutaneous administration
Study: NCT05455398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of round window niche enlargement via round window for inner ear drug delivery
Description: The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drum chamber drug injection
Description: Injection of drugs into the tympanic chamber through the tympanic membrane
Study: NCT06439290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy/breast augmentation
Description: Control group of PFAB and PMAB persons undergoing a mastectomy or breast augmentation surgery.
Study: NCT06345820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolux
Description: Evolux, enhanced monofocal IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Eyhance
Description: Tecnis Eyhance, enhanced monofocal IOL
Study: NCT06322498

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid
Study: NCT06144307

Intervention type: PROCEDURE
Intervention: plane block
Description: injection of local anesthetic to the myofascial plane

Intervention type: PROCEDURE
Intervention: plane block
Description: injection of local anesthetic to the myofascial plane
Study: NCT06530095

Intervention type: OTHER
Intervention: prone positioning
Description: prone positioning

Intervention type: OTHER
Intervention: prone positioning
Description: prone positioning
Study: NCT06357286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work opportunities
Description: Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work opportunities
Description: Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
Study: NCT05827991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1565nm Non-ablative Fractional Laser
Description: 1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% minoxidil external use
Description: The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1565nm Non-ablative Fractional Laser combined with 5% minoxidil
Description: The two treatment mentioned above
Study: NCT06357286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work opportunities
Description: Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
Study: NCT05352191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: inhaled 800ug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beclomethasone
Description: inhaled 800ug
Study: NCT06196307

Intervention type: COMBINATION_PRODUCT
Intervention: Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization
Description: Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)

Intervention type: COMBINATION_PRODUCT
Intervention: Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization
Description: Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)
Study: NCT06553872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
Study: NCT05137054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion
Study: NCT05268848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermographic photo
Description: Barefoot patient, thermographic photo of the sole of the feet is taken

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermographic photo
Description: Barefoot patient, thermographic photo of the sole of the feet is taken

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermographic photo
Description: Barefoot patient, thermographic photo of the sole of the feet is taken
Study: NCT05137054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion
Study: NCT04689308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH048
Description: Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH048
Description: Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
Study: NCT04775823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid composite nano-ceramic
Description: Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
Study: NCT05137054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion
Study: NCT06139484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: The stimulations were performed by Magstim RAPID.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation
Description: The stimulations were performed by Magstim RAPID.
Study: NCT05137054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered by mouth (PO) as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide is administered by mouth (PO) as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab is administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab is administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat is administered by mouth (PO) as a tablet
Study: NCT04104243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Men-Tailored DPP (Power-Up)
Description: Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
Study: NCT05912426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-sodium potassium-enriched salt
Description: Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
Study: NCT05904093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
Study: NCT05975333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: Participants will be asked to write about their experiences with cancer, guided by several specific open-ended writing prompts to spark ideas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: Following completion of the writing exercise, participants will reflect on their experiences with the writing intervention in a semi-structured private interview with a member of the research team.
Study: NCT05441813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Standard of care with the addition of virgin coconut oil mouth rinse
Study: NCT06349980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX53 (1000mg)
Description: HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
Study: NCT06475404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: verenafusp alfa 6 mg/kg
Description: Single intravenous administration of 6 mg/kg of verenafusp alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: verenafusp alfa 9 mg/kg
Description: Single intravenous administration of 9 mg/kg of verenafusp alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: verenafusp alfa 12 mg/kg
Description: Single intravenous administration of 12 mg/kg of verenafusp alfa
Study: NCT06349980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX53 (2000mg)
Description: HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX10
Description: HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX04
Description: HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching HLX53 will be administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT06448221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a web-based Relationship Teaching(RT)/communication education programs
Description: receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helper of Emotional Assessment Relationship Teaching (HEART) program
Description: receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
Study: NCT05194020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Services
Description: Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
Study: NCT06542458

Intervention type: BEHAVIORAL
Intervention: Assessments
Description: Participants will undergo a standard battery of neuropsychological measures, behavioral questionnaire, and functional assessment to monitor cognition and function over time. Clinical data obtained as part of standard of care will be collected from the medical record

Intervention type: OTHER
Intervention: Neuroimaging volumetric measures
Description: Neuroimaging volumetric measures will be obtained from already conducted standard of care neuroimaging.

Intervention type: OTHER
Intervention: Biofluid samples
Description: Biofluid sampling data will be obtained through another protocol. All participants will be required to sign that consent to participate in this trial.
Study: NCT06562764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling by the Trained Pharmacist
Description: The intervention group 1 is verbally counselled about the proper use of their inhaler devices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictograms Cards and Counselling by the Trained Pharmacist
Description: The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
Study: NCT05138003

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiac MRI
Description: T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RootiRx for the ECG monitoring during the cycling ride
Description: The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate \> 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
Study: NCT04662593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Health Program
Description: A mind-body-spirit intervention to improve health and well-being including weight loss.
Study: NCT05442385

Intervention type: OTHER
Intervention: Evidence based management
Description: clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment